Cefuroxime plus Azithromycin to reduce neonatal sepsis in preterm premature rupture of membranes between 24-33+6 weeks of gestation: a randomized controlled trial

Ratchasapisek Sompoch grant0 个研究点目标入组 110 人开始时间: 2021年7月24日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1.Women with singleton pregnancy between 24 - 33+6 weeks of gestational age.
•2.Women with first episode of premature rupture of membrane
•3.No evidence of intra-amniotic infection (chorioamnionitis)*
•4.Reassuring fetus evaluated by nonstress test (NST) or biophysical profile (BPP)*
•* Subsequent discovery of an evidence of intraamniotic infection (chorioamnionitis) or non-reassuring fetus is not an exclusion.

•1.Women with preterm labor with spontaneous rupture of membrane
•2.Immunocompromised status such as human immunodeficiency virus infection, over diabetes mellitus etc.
•3.Women with an autoimmune disease such as systemic lupus erythematosus,
•rheumatoid arthritis and anti-phospholipid syndromes etc.
•4. Women with known infection such as septicemia, pneumonia and pyelonephritis etc.
•5.Women with already prescribed antibiotics within 7 days before the onset of preterm premature rupture of membrane.
•6.History of Penicillin, Cephalosporin or Macrolide allergy.
•7.Women with a contraindication for expectant management in case of preterm premature rupture of membrane such as intraamniotic infection, fetal non-reassuring.
•8.Women with a fetal lethal anomaly *
•9.History of obstetric operation or procedure in the current pregnancy such as cervical cerclage, fetal surgery) and Amniocentesis etc.
•10.Women with abdominal trauma before the onset of preterm premature rupture of membrane.
•11.Women with an active genital lesion such as genital herpes, herpes zoster, and Condyloma accuminata etc.

发起方

Ratchasapisek Sompoch grant